Proceedings of the National Academy of Sciences · 13 November 2026 · From issue 67
Selectively disrupting lysine acetyltransferase p300 and ZEB1 interaction prevents tumor progression while enhancing antitumor immunity
In mice, a new drug blocked a cancer protein's stabilizer and shrank tumors.
Jing-Yu Luo, Bo-Xue Ren et al.
A helper protein tags a cancer-driving protein called ZEB1 with a small chemical mark, making ZEB1 more stable. This helps tumors hide from the immune system and grow faster. In mice, a new drug called WY6 blocked this process, shrank tumors, and worked even better alongside existing immune therapy drugs.
Integrity screen: passed (3 checks) Checked 15 November 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue